These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

914 related articles for article (PubMed ID: 32631382)

  • 41. Glycolysis module activated by hypoxia-inducible factor 1alpha is related to the aggressive phenotype of hepatocellular carcinoma.
    Hamaguchi T; Iizuka N; Tsunedomi R; Hamamoto Y; Miyamoto T; Iida M; Tokuhisa Y; Sakamoto K; Takashima M; Tamesa T; Oka M
    Int J Oncol; 2008 Oct; 33(4):725-31. PubMed ID: 18813785
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Eukaryotic translation initiation factor 5A2 promotes metabolic reprogramming in hepatocellular carcinoma cells.
    Cao TT; Lin SH; Fu L; Tang Z; Che CM; Zhang LY; Ming XY; Liu TF; Tang XM; Tan BB; Xiang D; Li F; Chan OY; Xie D; Cai Z; Guan XY
    Carcinogenesis; 2017 Jan; 38(1):94-104. PubMed ID: 27879277
    [TBL] [Abstract][Full Text] [Related]  

  • 43. LINC00365 functions as a tumor suppressor by inhibiting HIF-1α-mediated glucose metabolism reprogramming in breast cancer.
    Liu B; Qu X; Wang J; Xu L; Zhang L; Xu B; Su J; Bian X
    Exp Cell Res; 2023 Apr; 425(1):113514. PubMed ID: 36804531
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Androgen Receptor Stimulates Hexokinase 2 and Induces Glycolysis by PKA/CREB Signaling in Hepatocellular Carcinoma.
    Sun RF; Zhao CY; Chen S; Yu W; Zhou MM; Gao CR
    Dig Dis Sci; 2021 Mar; 66(3):802-813. PubMed ID: 32274668
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Galangin suppresses hepatocellular carcinoma cell proliferation by reversing the Warburg effect.
    Wang Y; Lin B; Li H; Lan L; Yu H; Wu S; Wu J; Zhang H
    Biomed Pharmacother; 2017 Nov; 95():1295-1300. PubMed ID: 28938520
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Glycolysis maintains AMPK activation in sorafenib-induced Warburg effect.
    Guo S; Zhang C; Zeng H; Xia Y; Weng C; Deng Y; Wang L; Wang H
    Mol Metab; 2023 Nov; 77():101796. PubMed ID: 37696356
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
    Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
    Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hypoxia inducible factor in hepatocellular carcinoma: A therapeutic target.
    Lin D; Wu J
    World J Gastroenterol; 2015 Nov; 21(42):12171-8. PubMed ID: 26576101
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Switching of pyruvate kinase isoform L to M2 promotes metabolic reprogramming in hepatocarcinogenesis.
    Wong CC; Au SL; Tse AP; Xu IM; Lai RK; Chiu DK; Wei LL; Fan DN; Tsang FH; Lo RC; Wong CM; Ng IO
    PLoS One; 2014; 9(12):e115036. PubMed ID: 25541689
    [TBL] [Abstract][Full Text] [Related]  

  • 50. FLIP(L) is critical for aerobic glycolysis in hepatocellular carcinoma.
    Lei S; Yang J; Chen C; Sun J; Yang L; Tang H; Yang T; Chen A; Zhao H; Li Y; Du X
    J Exp Clin Cancer Res; 2016 May; 35():79. PubMed ID: 27178057
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Involvement of lncRNAs in the regulation of aerobic glycolysis in hepatocellular carcinoma: Main functions, regulatory mechanisms and potential therapeutic implications (Review).
    Huang Q; Liang Z; Huang Q; Li X; Xia J; Huang L; Huang LB; Ou C
    Oncol Rep; 2024 Jun; 51(6):. PubMed ID: 38666534
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Circular RNA MAT2B Promotes Glycolysis and Malignancy of Hepatocellular Carcinoma Through the miR-338-3p/PKM2 Axis Under Hypoxic Stress.
    Li Q; Pan X; Zhu D; Deng Z; Jiang R; Wang X
    Hepatology; 2019 Oct; 70(4):1298-1316. PubMed ID: 31004447
    [TBL] [Abstract][Full Text] [Related]  

  • 53. miR-592/WSB1/HIF-1α axis inhibits glycolytic metabolism to decrease hepatocellular carcinoma growth.
    Jia YY; Zhao JY; Li BL; Gao K; Song Y; Liu MY; Yang XJ; Xue Y; Wen AD; Shi L
    Oncotarget; 2016 Jun; 7(23):35257-69. PubMed ID: 27153552
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Glycolysis in Chronic Liver Diseases: Mechanistic Insights and Therapeutic Opportunities.
    Qu H; Liu J; Zhang D; Xie R; Wang L; Hong J
    Cells; 2023 Jul; 12(15):. PubMed ID: 37566009
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Regulation of HK2 expression through alterations in CpG methylation of the HK2 promoter during progression of hepatocellular carcinoma.
    Lee HG; Kim H; Son T; Jeong Y; Kim SU; Dong SM; Park YN; Lee JD; Lee JM; Park JH
    Oncotarget; 2016 Jul; 7(27):41798-41810. PubMed ID: 27260001
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Why may citrate sodium significantly increase the effectiveness of transarterial chemoembolization in hepatocellular carcinoma?
    Icard P; Simula L; Wu Z; Berzan D; Sogni P; Dohan A; Dautry R; Coquerel A; Lincet H; Loi M; Fuks D
    Drug Resist Updat; 2021 Dec; 59():100790. PubMed ID: 34924279
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The miR-125a/HK2 axis regulates cancer cell energy metabolism reprogramming in hepatocellular carcinoma.
    Jin F; Wang Y; Zhu Y; Li S; Liu Y; Chen C; Wang X; Zen K; Li L
    Sci Rep; 2017 Jun; 7(1):3089. PubMed ID: 28596599
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Integrated analyses identify miR-34c-3p/MAGI3 axis for the Warburg metabolism in hepatocellular carcinoma.
    Weng Q; Chen M; Yang W; Li J; Fan K; Xu M; Weng W; Lv X; Fang S; Zheng L; Song J; Zhao Z; Fan X; Ji J
    FASEB J; 2020 Apr; 34(4):5420-5434. PubMed ID: 32080912
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inhibition of GSK-3β activity suppresses HCC malignant phenotype by inhibiting glycolysis via activating AMPK/mTOR signaling.
    Fang G; Zhang P; Liu J; Zhang X; Zhu X; Li R; Wang H
    Cancer Lett; 2019 Oct; 463():11-26. PubMed ID: 31404613
    [TBL] [Abstract][Full Text] [Related]  

  • 60. ELK3 promotes the migration and invasion of liver cancer stem cells by targeting HIF-1α.
    Lee JH; Hur W; Hong SW; Kim JH; Kim SM; Lee EB; Yoon SK
    Oncol Rep; 2017 Feb; 37(2):813-822. PubMed ID: 27959451
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 46.